[go: up one dir, main page]

PE20250785A1 - PHARMACEUTICAL SOLUTIONS OF ANTI-N3PGLU Aß ANTIBODIES AND THEIR USES - Google Patents

PHARMACEUTICAL SOLUTIONS OF ANTI-N3PGLU Aß ANTIBODIES AND THEIR USES

Info

Publication number
PE20250785A1
PE20250785A1 PE2025000205A PE2025000205A PE20250785A1 PE 20250785 A1 PE20250785 A1 PE 20250785A1 PE 2025000205 A PE2025000205 A PE 2025000205A PE 2025000205 A PE2025000205 A PE 2025000205A PE 20250785 A1 PE20250785 A1 PE 20250785A1
Authority
PE
Peru
Prior art keywords
seq
n3pglu
pharmaceutical solutions
pharmaceutical
antibodies
Prior art date
Application number
PE2025000205A
Other languages
Spanish (es)
Inventor
Vincent John Corvari
Nicole H Durbin
Anant Navanithan Sharma
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20250785A1 publication Critical patent/PE20250785A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se relaciona con soluciones farmaceuticas de ciertos anticuerpos anti-N3pGlu ABeta. Tambien se describen usos de tales soluciones farmaceuticas, que incluyen el uso en el tratamiento de la enfermedad de Alzheimer. Se trata de una solucion farmaceutica que comprende un anticuerpo anti-N3pGlu ABeta que comprende (a) una region variable de cadena ligera (LCVR) que comprende una LCDR1 de la sec. con num. de ident.: 5, una LCDR2 de la sec. con num. de ident.: 6, y una LCDR3 de la sec. con num. de ident.: 7, y (b) una region variable de cadena pesada (HCVR) que comprende una HCDR1 de la sec. con num. de ident.: 8, una HCDR2 de la sec. con num. de ident.: 9, y una HCDR3 de la sec. con num. de ident.: 10, un regulador, un agente de tonicidad, un surfactante, y un excipiente opcional; en cantidades que son suficientes en combinacion para una solucion farmaceutica.It relates to pharmaceutical solutions of certain anti-N3pGlu ABeta antibodies. Also described are uses of such pharmaceutical solutions, including use in the treatment of Alzheimer's disease. It is a pharmaceutical solution comprising an anti-N3pGlu ABeta antibody comprising (a) a light chain variable region (LCVR) comprising an LCDR1 of SEQ ID NO: 5, an LCDR2 of SEQ ID NO: 6, and an LCDR3 of SEQ ID NO: 7, and (b) a heavy chain variable region (HCVR) comprising an HCDR1 of SEQ ID NO: 8, an HCDR2 of SEQ ID NO: 9, and an HCDR3 of SEQ ID NO: 10. of ident.: 10, a regulator, a tonicity agent, a surfactant, and an optional excipient; in amounts that are sufficient in combination for a pharmaceutical solution.

PE2025000205A 2022-07-21 2023-07-20 PHARMACEUTICAL SOLUTIONS OF ANTI-N3PGLU Aß ANTIBODIES AND THEIR USES PE20250785A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263369033P 2022-07-21 2022-07-21
PCT/US2023/070540 WO2024020470A1 (en) 2022-07-21 2023-07-20 PHARMACEUTICAL SOLUTIONS OF ANTI-N3pGlu Aβ ANTIBODIES AND USES THEREOF

Publications (1)

Publication Number Publication Date
PE20250785A1 true PE20250785A1 (en) 2025-03-14

Family

ID=87576063

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2025000205A PE20250785A1 (en) 2022-07-21 2023-07-20 PHARMACEUTICAL SOLUTIONS OF ANTI-N3PGLU Aß ANTIBODIES AND THEIR USES

Country Status (17)

Country Link
EP (1) EP4558166A1 (en)
JP (1) JP2025525587A (en)
KR (1) KR20250037554A (en)
CN (1) CN119604302A (en)
AR (1) AR129994A1 (en)
AU (1) AU2023309007A1 (en)
CA (1) CA3261418A1 (en)
CL (1) CL2025000145A1 (en)
CO (1) CO2025000508A2 (en)
CR (1) CR20250023A (en)
DO (1) DOP2025000005A (en)
IL (1) IL318102A (en)
MA (1) MA71558A (en)
MX (1) MX2025000820A (en)
PE (1) PE20250785A1 (en)
TW (1) TW202421188A (en)
WO (1) WO2024020470A1 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3042917T (en) * 2010-08-12 2018-05-10 Eli Lilly And Company ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF

Also Published As

Publication number Publication date
MA71558A (en) 2025-05-30
IL318102A (en) 2025-02-01
CR20250023A (en) 2025-02-17
CN119604302A (en) 2025-03-11
CL2025000145A1 (en) 2025-05-30
MX2025000820A (en) 2025-03-07
JP2025525587A (en) 2025-08-05
EP4558166A1 (en) 2025-05-28
CA3261418A1 (en) 2024-01-25
WO2024020470A1 (en) 2024-01-25
TW202421188A (en) 2024-06-01
CO2025000508A2 (en) 2025-02-04
AR129994A1 (en) 2024-10-23
KR20250037554A (en) 2025-03-17
AU2023309007A1 (en) 2025-01-30
DOP2025000005A (en) 2025-02-28

Similar Documents

Publication Publication Date Title
PE20210045A1 (en) AGONIST ANTIBODIES AGAINST PD-1 AND USES OF THESE
ES2564252T3 (en) Anti-beta-amyloid N3pGlu peptide antibodies and uses thereof
PE20200011A1 (en) ANTI-PEPTIDE BETA AMYLOID N3pGlu ANTIBODIES AND THEIR USES
ES2656000T3 (en) Antibodies against CGRP
AR110203A1 (en) ANTI-TIM-3 ANTIBODIES FOR COMBINATION WITH ANTI-PD-1 ANTIBODIES
PE20212088A1 (en) ANTI-TAU ANTIBODIES AND THEIR USE
AR126019A1 (en) ANTIBODIES AGAINST ENTPD2, COMBINATION THERAPIES AND METHODS OF USE OF ANTIBODIES AND COMBINATION THERAPIES
PE20200294A1 (en) ANTIBODIES THAT SPECIFICALLY BIND PD-1 AND METHODS OF USE
MX2019007848A (en) Anti-pd-1 antibodies and uses thereof.
PE20210180A1 (en) ANTI-CD33 ANTIBODIES, ANTI-CD33 / ANTI-CD3 BISPECIFIC ANTIBODIES AND USES OF THEM
PE20190630A1 (en) ANTI-TIM-3 ANTIBODIES
PE20091205A1 (en) IL-6 ANTI-RECEPTOR ANTIBODY
PE20080119A1 (en) ANTI-5TA ANTIBODIES AND THEIR USES
PE20191045A1 (en) ANTI-IL-33 ANTIBODIES AND USES OF THEM
AR103713A1 (en) ANTIBODIES AGAINST TAU AND ITS USES
CO6230999A2 (en) ANTI-SCLEROSTINE ANTIBODY
PE20091351A1 (en) HUMANIZED ANTIBODIES SPECIFIC TO THE VON WILLEBRAND FACTOR
AR110719A1 (en) HUMAN ANTIBODIES TO HEMOLISINE TOXIN A DE S. AUREUS
RU2015110981A (en) COMBINATIONS AND THEIR APPLICATION
PE20201494A1 (en) ANTI-PACAP ANTIBODY
AR125212A1 (en) PROTEINS INCLUDING CD3 ANTIGEN-BINDING DOMAINS AND THEIR USES
RU2014103490A (en) COMBINED THERAPY USING AN ANTIBODY TO CD19 AND PURIN ANALOGUE
PE20212185A1 (en) FORMULATION OF THERAPEUTIC ANTIBODIES
RU2017137496A (en) Medication for the treatment of multiple myeloma (MM)
UY39878A (en) PHARMACEUTICAL COMPOSITION OF ANTI-PD-1 ANTIBODY AND ITS USE